{"success":true,"data":{"pressRelease":{"id":"129231","rtpr_id":"nGNE7qfbDk","ticker":"VTAK","exchange":"NYSE American","all_tickers":["VTAK"],"title":"Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany","author":"Globe Newswire","published_at":"2026-08-27T12:00:00.350Z","article_body":"Received First LockeT Purchase Order Through Cardinal Health which serves\napproximately 90% of U.S. Hospitals though its Medical Products business \n\nJohns Hopkins Hospital, a world-renowned academic medical center, Places First\nOrder for LockeT, VTAK’s suture retention device\n\nPlaces its first VIVO 3D Imaging System with a hospital in Germany, one of the\nlargest electrophysiology markets in Europe.\n\nFORT MILL, S.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Catheter Precision,\nInc.’s (NYSE American: VTAK) medical device business unit specializing in\ncardiac electrophysiology solutions, today announced significant commercial\ngrowth across its LockeT and VIVO product lines, marked by new U.S.\ndistribution channels, premier hospital adoption, and international expansion.\n\nKey Commercial Highlights:\n* Cardinal Health Strategic Reach: Catheter Precision received its first\npurchase order for LockeT via Cardinal Health. As one of the nation's largest\ndistributors—servicing roughly 90% of U.S. hospitals—Cardinal Health\nprovides LockeT a massive streamlined supply chain network across the U.S.\nhealthcare market.\n* Johns Hopkins Adoption: The Company secured its first purchase order for\nLockeT from Johns Hopkins in Baltimore MD, validating the clinical value of\nthe device within one of the world's premier academic medical institutions.\n* German VIVO System Placement: Expanding its European footprint, Catheter\nPrecision signed a new placement contract for its VIVO System in Germany,\ncontinuing its strategy to grow international use.\n\"These achievements highlight tangible progress across both our LockeT and\nVIVO product portfolios,\" said David Jenkins, Chief Executive Officer of\nCatheter Precision. \"Securing our first Cardinal Health order grants us\nimmediate access to an extensive domestic distribution network to drive\nbroader market adoption. Concurrently, our milestone order with Johns Hopkins\nvalidates our clinical offering, while our new VIVO contract in Germany\nunderscores steady international demand.\"\n\nJenkins added, \"We are beginning to realize the returns on our commercial\ninfrastructure investments. Our focus remains on driving multi-channel growth\nthrough expanded U.S. distribution, direct enterprise hospital relationships,\nand targeted international expansion. Catheter Precision remains committed to\nscaling its global footprint across top-tier health systems, physicians, and\nglobal distribution partners.”\n\nAbout Catheter Precision, Inc.\nCatheter Precision, Inc. (NYSE American: VTAK) is an innovative medical device\ncompany focused on developing breakthrough solutions for cardiac\nelectrophysiology procedures. Its core product portfolio includes the VIVO™\nsystem, a non-invasive 3D imaging platform designed to assist\nelectrophysiologists in mapping cardiac arrhythmias, and LockeT, a suture\nretention device designed to assist in vascular closure post-procedure.\n\nAbout LockeT\nCatheter Precision’s LockeT® is a suture retention device indicated for\nwound healing by distributing suture tension over a larger area in conjunction\nwith standard-of-care closure techniques. LockeT is intended to temporarily\nsecure sutures and aid clinicians in locating and removing sutures\nefficiently. LockeT is a sterile Class I product registered with the FDA and\nhas received CE Mark approval.\n\nAbout VIVO\nCatheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive\n3D imaging system that enables physicians to identify the origin of\nventricular arrhythmias prior to an electrophysiology procedure, potentially\nstreamlining procedural workflow. VIVO has received marketing clearance from\nthe U.S. FDA and carries the CE Mark.\n\nAbout Catheter Precision\nCatheter Precision, Inc. (NYSE American: VTAK) is an innovative U.S.-based\nmedical device company focused on developing and commercializing technologies\ndesigned to improve the treatment of cardiac arrhythmias. The Company’s\nprimary commercial products include the VIVO System and LockeT.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\napplicable federal securities laws. Forward-looking statements include\nstatements regarding the potential commercial adoption of LockeT and VIVO,\nexpansion of distribution channels, future product sales, hospital adoption,\ninternational expansion and the potential impact of the Company’s commercial\nstrategy. These statements are based on current expectations and assumptions\nand involve risks and uncertainties that could cause actual results to differ\nmaterially from those expressed or implied. Readers are encouraged to review\nthe Company’s filings with the Securities and Exchange Commission, including\nits Forms 10-K and 10-Q, for additional information regarding these risks.\n\nContact\nInvestor Relations\nIR@catheterprecision.com\n973-691-2000","article_body_html":"","raw_payload":{"data":{"id":"nGNE7qfbDk","title":"Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany","author":"Globe Newswire","ticker":"VTAK","created":"2026-08-27T12:00:00.350Z","tickers":["VTAK"],"exchange":"NYSE American","article_body":"Received First LockeT Purchase Order Through Cardinal Health which serves\napproximately 90% of U.S. Hospitals though its Medical Products business \n\nJohns Hopkins Hospital, a world-renowned academic medical center, Places First\nOrder for LockeT, VTAK’s suture retention device\n\nPlaces its first VIVO 3D Imaging System with a hospital in Germany, one of the\nlargest electrophysiology markets in Europe.\n\nFORT MILL, S.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Catheter Precision,\nInc.’s (NYSE American: VTAK) medical device business unit specializing in\ncardiac electrophysiology solutions, today announced significant commercial\ngrowth across its LockeT and VIVO product lines, marked by new U.S.\ndistribution channels, premier hospital adoption, and international expansion.\n\nKey Commercial Highlights:\n* Cardinal Health Strategic Reach: Catheter Precision received its first\npurchase order for LockeT via Cardinal Health. As one of the nation's largest\ndistributors—servicing roughly 90% of U.S. hospitals—Cardinal Health\nprovides LockeT a massive streamlined supply chain network across the U.S.\nhealthcare market.\n* Johns Hopkins Adoption: The Company secured its first purchase order for\nLockeT from Johns Hopkins in Baltimore MD, validating the clinical value of\nthe device within one of the world's premier academic medical institutions.\n* German VIVO System Placement: Expanding its European footprint, Catheter\nPrecision signed a new placement contract for its VIVO System in Germany,\ncontinuing its strategy to grow international use.\n\"These achievements highlight tangible progress across both our LockeT and\nVIVO product portfolios,\" said David Jenkins, Chief Executive Officer of\nCatheter Precision. \"Securing our first Cardinal Health order grants us\nimmediate access to an extensive domestic distribution network to drive\nbroader market adoption. Concurrently, our milestone order with Johns Hopkins\nvalidates our clinical offering, while our new VIVO contract in Germany\nunderscores steady international demand.\"\n\nJenkins added, \"We are beginning to realize the returns on our commercial\ninfrastructure investments. Our focus remains on driving multi-channel growth\nthrough expanded U.S. distribution, direct enterprise hospital relationships,\nand targeted international expansion. Catheter Precision remains committed to\nscaling its global footprint across top-tier health systems, physicians, and\nglobal distribution partners.”\n\nAbout Catheter Precision, Inc.\nCatheter Precision, Inc. (NYSE American: VTAK) is an innovative medical device\ncompany focused on developing breakthrough solutions for cardiac\nelectrophysiology procedures. Its core product portfolio includes the VIVO™\nsystem, a non-invasive 3D imaging platform designed to assist\nelectrophysiologists in mapping cardiac arrhythmias, and LockeT, a suture\nretention device designed to assist in vascular closure post-procedure.\n\nAbout LockeT\nCatheter Precision’s LockeT® is a suture retention device indicated for\nwound healing by distributing suture tension over a larger area in conjunction\nwith standard-of-care closure techniques. LockeT is intended to temporarily\nsecure sutures and aid clinicians in locating and removing sutures\nefficiently. LockeT is a sterile Class I product registered with the FDA and\nhas received CE Mark approval.\n\nAbout VIVO\nCatheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive\n3D imaging system that enables physicians to identify the origin of\nventricular arrhythmias prior to an electrophysiology procedure, potentially\nstreamlining procedural workflow. VIVO has received marketing clearance from\nthe U.S. FDA and carries the CE Mark.\n\nAbout Catheter Precision\nCatheter Precision, Inc. (NYSE American: VTAK) is an innovative U.S.-based\nmedical device company focused on developing and commercializing technologies\ndesigned to improve the treatment of cardiac arrhythmias. The Company’s\nprimary commercial products include the VIVO System and LockeT.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\napplicable federal securities laws. Forward-looking statements include\nstatements regarding the potential commercial adoption of LockeT and VIVO,\nexpansion of distribution channels, future product sales, hospital adoption,\ninternational expansion and the potential impact of the Company’s commercial\nstrategy. These statements are based on current expectations and assumptions\nand involve risks and uncertainties that could cause actual results to differ\nmaterially from those expressed or implied. Readers are encouraged to review\nthe Company’s filings with the Securities and Exchange Commission, including\nits Forms 10-K and 10-Q, for additional information regarding these risks.\n\nContact\nInvestor Relations\nIR@catheterprecision.com\n973-691-2000"},"type":"article","timestamp":"2026-08-27T12:00:00.493988107Z","server_sent_at_ms":1787832000493},"received_at":"2026-08-27T12:00:00.544Z","source_url":"https://www.globenewswire.com/news-release/2026/08/27/3351933/0/en/catheter-precision-achieves-major-commercial-milestones-with-cardinal-health-johns-hopkins-and-the-placement-of-the-first-vivo-system-in-germany.html"},"analysis":{"id":"118143","press_release_id":"129231","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Catheter Precision secured its first purchase order for LockeT through Cardinal Health, gaining entry into a distribution network that services approximately 90% of U.S. hospitals.\n\nThe company also received its initial order for LockeT from Johns Hopkins Hospital, providing significant clinical validation from a top-tier academic medical institution.\n\nFurthering its international growth, Catheter Precision placed its first VIVO 3D Imaging System in Germany, expanding its footprint in a key European electrophysiology market.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Distribution unlock with Cardinal Health and flagship validation from Johns Hopkins mark key commercial inflection points."},"keyFigures":{"customDimensions":{"cardinal_health_market_coverage":"90%"}},"quotedText":"Securing our first Cardinal Health order grants us immediate access to an extensive domestic distribution network to drive broader market adoption.","namedEntities":{"people":[{"name":"David Jenkins","role":"Chief Executive Officer"}],"products":["LockeT","VIVO 3D Imaging System"],"companies":[{"name":"Catheter Precision, Inc.","ticker":"VTAK"},{"name":"Cardinal Health","relationship":"distributor"},{"name":"Johns Hopkins Hospital","relationship":"customer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Secured distribution access through Cardinal Health (servicing ~90% of U.S. hospitals) and landmark purchase orders from Johns Hopkins, representing significant commercial validation and channel expansion despite lack of disclosed financial figures."},"tickerRelevance":{"others":[],"primary":"VTAK"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"commercial_milestone","partnerPrestige":"high"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Catheter Precision secured its first purchase order for LockeT through Cardinal Health, gaining entry into a distribution network that services approximately 90% of U.S. hospitals.\n\nThe company also received its initial order for LockeT from Johns Hopkins Hospital, providing significant clinical validation from a top-tier academic medical institution.\n\nFurthering its international growth, Catheter Precision placed its first VIVO 3D Imaging System in Germany, expanding its footprint in a key European electrophysiology market.","key_figures":{"customDimensions":{"cardinal_health_market_coverage":"90%"}},"named_entities":{"people":[{"name":"David Jenkins","role":"Chief Executive Officer"}],"products":["LockeT","VIVO 3D Imaging System"],"companies":[{"name":"Catheter Precision, Inc.","ticker":"VTAK"},{"name":"Cardinal Health","relationship":"distributor"},{"name":"Johns Hopkins Hospital","relationship":"customer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T12:25:51.704Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"commercial_milestone","partnerPrestige":"high"}},"durationMs":109993,"modelName":"glm-4.7"}}